Scholarlink

Background <p>Endoscopic lung volume reduction (ELVR) using endobronchial valves is an established treatment for advanced COPD and emphysema. To reduce procedure-related complications such as pneumonia or exacerbations, peri-interventional antibiotic prophylaxis is commonly used; however, its clinical benefit remains uncertain. We aimed to evaluate the effect of different peri-interventional antibiotic strategies in a German COPD cohort.</p> Methods <p>Comparative analyses were performed using data from 900 patients enrolled in the multicentre, observational German Lung Emphysema Registry (LE-Registry). Patients were categorized by peri-interventional antibiotic strategy: single-dose prophylaxis, prolonged prophylaxis for 5–7&#xa0;days, or no prophylaxis. Baseline characteristics, airway colonization, lung function, symptom burden, exercise capacity, and adverse events were assessed up to three months after ELVR.</p> Results <p>Among 900 patients undergoing ELVR, 104 received single-dose prophylaxis, 344 prolonged 5–7-day prophylaxis, and 309 no antibiotic prophylaxis. Clinical improvements in lung function, symptom burden, and exercise capacity over three months were similar across all groups. Exacerbations occurred in 11.5% of patients receiving single-dose prophylaxis (12/104), 7.6% with prolonged prophylaxis (26/344), and 5.5% without prophylaxis (17/309; <i>p</i> = 0.12). Pneumonia was observed in 7.7% (8/104), 3.2% (11/344), and 3.2% (10/309), respectively (<i>p</i> = 0.087). Antibiotic-related adverse events were infrequent and mild, occurring only in the prolonged prophylaxis group.</p> Conclusion <p>Peri-interventional antibiotic prophylaxis, whether single-dose or prolonged, did not improve clinical outcomes or reduce complication rates following ELVR. These findings indicate limited clinical benefit and support a more targeted, indication-based use of antibiotics in this setting.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Peri-interventional antibiotic prophylaxis in endoscopic valve implantation for lung volume reduction in COPD patients: results from a German multicenter observational cohort

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月13日

查看全文
  • Eva Pappe,
  • Hadis Darvishi,
  • Thomas Sgarbossa,
  • Jacopo Saccomano,
  • Kaid Darwiche,
  • Stefan Andreas,
  • Stephan Eisenmann,
  • Bernd Schmidt,
  • Wolfgang Gesierich,
  • Nicolas Dickgreber,
  • Christian Geltner,
  • Joachim Hans Ficker,
  • Angelique Holland,
  • Björn Schwick,
  • Stephan Eggeling,
  • Ralf Eberhardt,
  • Christian Grah,
  • Christoph Hünermann,
  • Urte Sommerwerck,
  • Andreas Fertl,
  • Sylke Kurz,
  • Peter Schramm,
  • Dinah von Schöning,
  • Leif Erik Sander,
  • Martin Witzenrath,
  • Ralf-Harto Hübner

摘要

Background

Endoscopic lung volume reduction (ELVR) using endobronchial valves is an established treatment for advanced COPD and emphysema. To reduce procedure-related complications such as pneumonia or exacerbations, peri-interventional antibiotic prophylaxis is commonly used; however, its clinical benefit remains uncertain. We aimed to evaluate the effect of different peri-interventional antibiotic strategies in a German COPD cohort.

Methods

Comparative analyses were performed using data from 900 patients enrolled in the multicentre, observational German Lung Emphysema Registry (LE-Registry). Patients were categorized by peri-interventional antibiotic strategy: single-dose prophylaxis, prolonged prophylaxis for 5–7 days, or no prophylaxis. Baseline characteristics, airway colonization, lung function, symptom burden, exercise capacity, and adverse events were assessed up to three months after ELVR.

Results

Among 900 patients undergoing ELVR, 104 received single-dose prophylaxis, 344 prolonged 5–7-day prophylaxis, and 309 no antibiotic prophylaxis. Clinical improvements in lung function, symptom burden, and exercise capacity over three months were similar across all groups. Exacerbations occurred in 11.5% of patients receiving single-dose prophylaxis (12/104), 7.6% with prolonged prophylaxis (26/344), and 5.5% without prophylaxis (17/309; p = 0.12). Pneumonia was observed in 7.7% (8/104), 3.2% (11/344), and 3.2% (10/309), respectively (p = 0.087). Antibiotic-related adverse events were infrequent and mild, occurring only in the prolonged prophylaxis group.

Conclusion

Peri-interventional antibiotic prophylaxis, whether single-dose or prolonged, did not improve clinical outcomes or reduce complication rates following ELVR. These findings indicate limited clinical benefit and support a more targeted, indication-based use of antibiotics in this setting.